Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Stem cell factor contributes to tumorigenesis of mast cells via an autocrine/paracrine mechanism.

Amagai Y, Tanaka A, Matsuda A, Jung K, Ohmori K, Matsuda H.

J Leukoc Biol. 2013 Feb;93(2):245-50. doi: 10.1189/jlb.0512245. Epub 2012 Nov 2.

PMID:
23125456
2.

Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.

Takeuchi Y, Fujino Y, Watanabe M, Nakagawa T, Ohno K, Sasaki N, Sugano S, Tsujimoto H.

Vet Immunol Immunopathol. 2010 Oct 15;137(3-4):208-16. doi: 10.1016/j.vetimm.2010.05.009. Epub 2010 May 31.

PMID:
20591500
3.

Production of stem cell factor in canine mast cell tumors.

Amagai Y, Tanaka A, Jung K, Matsuda A, Oida K, Nishikawa S, Jang H, Ishizaka S, Matsuda H.

Res Vet Sci. 2014 Feb;96(1):124-6. doi: 10.1016/j.rvsc.2013.10.014. Epub 2013 Nov 7.

PMID:
24269079
4.

Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.

Hoermann G, Cerny-Reiterer S, Perné A, Klauser M, Hoetzenecker K, Klein K, Müllauer L, Gröger M, Nijman SM, Klepetko W, Valent P, Mayerhofer M.

Am J Pathol. 2011 May;178(5):2344-56. doi: 10.1016/j.ajpath.2011.01.020. Epub 2011 Mar 31.

5.

Regulation of normal and neoplastic human mast cell development in mastocytosis.

Metcalfe DD.

Trans Am Clin Climatol Assoc. 2005;116:185-203; discussion 203-4.

6.

A possible mechanism of mast cell proliferation in mastocytosis.

Kambe N, Miyachi Y.

J Dermatol. 2002 Jan;29(1):1-9. Review.

PMID:
11837566
7.

KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of merkel cell carcinoma in vitro.

Krasagakis K, Fragiadaki I, Metaxari M, Krüger-Krasagakis S, Tzanakakis GN, Stathopoulos EN, Eberle J, Tavernarakis N, Tosca AD.

J Cell Physiol. 2011 Apr;226(4):1099-109. doi: 10.1002/jcp.22431.

PMID:
20857409
8.

Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.

Noack F, Escribano L, Sotlar K, Nunez R, Schuetze K, Valent P, Horny HP.

Leuk Lymphoma. 2003 Feb;44(2):313-9.

PMID:
12688351
9.

Mastocytosis cells bearing a c-kit activating point mutation are characterized by hypersensitivity to stem cell factor and increased apoptosis.

Dror Y, Leaker M, Caruana G, Bernstein A, Freedman MH.

Br J Haematol. 2000 Mar;108(4):729-36.

PMID:
10792276
10.

The presence of membrane-bound stem cell factor on highly immature nonmetachromatic mast cells in the peripheral blood of a patient with aggressive systemic mastocytosis.

Castells MC, Friend DS, Bunnell CA, Hu X, Kraus M, Osteen RT, Austen KF.

J Allergy Clin Immunol. 1996 Oct;98(4):831-40.

PMID:
8876560
11.

Novel autocrine and paracrine loops of the stem cell factor/chymase network.

de Paulis A, Minopoli G, Dal Piaz F, Pucci P, Russo T, Marone G.

Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):422-5.

PMID:
10224464
12.

Human mast cells express stem cell factor.

Zhang S, Anderson DF, Bradding P, Coward WR, Baddeley SM, MacLeod JD, McGill JI, Church MK, Holgate ST, Roche WR.

J Pathol. 1998 Sep;186(1):59-66.

PMID:
9875141
13.

An immunohistochemical study of the bone marrow lesions of systemic mastocytosis: expression of stem cell factor by lesional mast cells.

Akin C, Jaffe ES, Raffeld M, Kirshenbaum AS, Daley T, Noel P, Metcalfe DD.

Am J Clin Pathol. 2002 Aug;118(2):242-7.

PMID:
12162685
14.

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.

Saleh R, Wedeh G, Herrmann H, Bibi S, Cerny-Reiterer S, Sadovnik I, Blatt K, Hadzijusufovic E, Jeanningros S, Blanc C, Legarff-Tavernier M, Chapiro E, Nguyen-Khac F, Subra F, Bonnemye P, Dubreuil P, Desplat V, Merle-Béral H, Willmann M, Rülicke T, Valent P, Arock M.

Blood. 2014 Jul 3;124(1):111-20. doi: 10.1182/blood-2013-10-534685. Epub 2014 Mar 27.

15.

Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis.

Longley BJ Jr, Morganroth GS, Tyrrell L, Ding TG, Anderson DM, Williams DE, Halaban R.

N Engl J Med. 1993 May 6;328(18):1302-7.

16.

The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis.

Taylor ML, Dastych J, Sehgal D, Sundstrom M, Nilsson G, Akin C, Mage RG, Metcalfe DD.

Blood. 2001 Aug 15;98(4):1195-9.

17.

Arthritis augments breast cancer metastasis: role of mast cells and SCF/c-Kit signaling.

Das Roy L, Curry JM, Sahraei M, Besmer DM, Kidiyoor A, Gruber HE, Mukherjee P.

Breast Cancer Res. 2013 Apr 11;15(2):R32. doi: 10.1186/bcr3412.

18.

Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.

Shivakrupa R, Bernstein A, Watring N, Linnekin D.

Cancer Res. 2003 Aug 1;63(15):4412-9.

19.

KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.

Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, Aldanondo I, Sanchez L, Dominguez M, Botana LM, Sanchez-Jimenez F, Sotlar K, Almeida J, Escribano L, Orfao A.

Blood. 2006 Oct 1;108(7):2366-72. Epub 2006 Jun 1.

20.

Recent advances in the understanding of mastocytosis: the role of KIT mutations.

Orfao A, Garcia-Montero AC, Sanchez L, Escribano L; REMA..

Br J Haematol. 2007 Jul;138(1):12-30. Review.

PMID:
17555444

Supplemental Content

Support Center